Abstract: An immunotoxin for use in the treatment of leishmaniasis A wherein the immunotoxin comprises a portion which is specifically binding to the cellular surface receptor CD64 as a component A and a cell killing portion as a component B, wherein the cell killing portion alters the function, gene expression, or viability of a cell thereby killing Leishmania-infected macrophages and by this eliminates Leishmania.

Abstract: The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against Plasmodium falciparum (P. falciparum) comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

Abstract: A compound formed from at least one component A comprising a binding domain for extra-cellular surface structures of a diseased proliferating cell that internalized upon binding of component A of said compound, and at least one component B, characterized in that component B is a polypeptide which amino acid sequence comprises a microtubule-associated protein (MAP) or comprises at least a partial sequence of the MAP, the partial sequence having maintained the binding function of the MAP to a microtubule.

Abstract: A polypeptide having a binding affinity to CD64 of at least 10?9 M for use in a treatment of a disease associated with an inflammation in combination with an anti-TNF-?, antibody.

Abstract: The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof; to nucleic acid molecules encoding said recombinant hCFPs, vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: A polypeptide having a serine protease variant of the human granzyme B set forth by SEQ ID NO: 1, wherein the serine protease variant has at least 95% identity to SEQ ID NO: 1 and has a substitution at the position that corresponds structurally or by amino acid sequence homology to position Arg201 of SEQ ID NO: 1, and wherein the serine protease variant has activity to cleave the motif Ile-Glu-Thr-Asp.

Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.

Abstract: A polypeptide in particular an antibody or antibody fragment is disclosed wherein the polypeptide is corresponding to certain complementarity determining regions CDR1, CDR2 and CDR3 of a heavy chain VH and a light chain VL of an antibody as well as a compound comprising the polypeptide, its use as diagnostic agent for acute myeloid leukemia subtype M2 and a kit comprising the compound.

Abstract: A polypeptide which binds to the surface of AML blast cells and is internalised upon binding to the AML blast cells.

Abstract: An immunomodulatory fusion protein (IFP) for converting pro-inflammatory M macrophages to anti-inflammatory M2 like phenotypes of macrophagesthe IFP having at least one component A and at least one component B wherein the component A is comprising or consisting of a binding domain for extra-cellular surface structures of a macrophage that internalizes said immunomodulatory fusion protein upon binding of component A of said immunomodulatory fusion protein, and the component B is modulating the macrophage and comprises or consists of a DNA oligonucleotide or RNA oligonucleotide or a chemical small molecule exhibiting modulatory functions to targeted macrophages or a polypeptide which amino acid sequence comprises or consists of a macrophage modulatory protein or comprises or consists of at least a partial sequence of the macrophage modulatory protein, the partial sequence having maintained the modulatory function of the macrophage modulatory protein.

Abstract: The technology provided herein relates to novel immunoproteases suitable to induce apotosis in selected diseased target cells, comprising the serine protease granzyme M, and methods for using such cytolytic fusion proteins for the treatment of various diseases, in particular for the treatment of cancer.

Abstract: A compound formed from at least one component A comprising a binding domain for extra-cellular surface structures of a diseased proliferating cell that internalized upon binding of component A of said compound, and at least one component B, characterized in that component B is a polypeptide which amino acid sequence comprises a microtubule-associated protein (MAP) or comprises at least a partial sequence of the MAP, the partial sequence having maintained the binding function of the MAP to a microtubule.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.

Abstract: A synthetic, soluble, endogenous complex formed from at least one component A and at least one component B, whereby component A comprises a binding domain for extra-cellular surface structures that internalize upon binding of component A of said complex, and component B has a constitutive catalytic kinase activity and effects cell biosynthesis/signalling including cell death after internalization. The complex allows to influence the growth and the physiology of cells. In particular said complex, nucleic acid molecules encoding it, cells transfected or transformed with these nucleic acid molecules are usable for the preparation of medicaments for the treatment of proliferative diseases, inflammatory diseases, allergies and autoimmune diseases.

Abstract: A compound comprising a photosensitizer covalently coupled to a protein selected from the group consisting of antibodies or their derivatives or fragments thereof, synthetic peptides such as scFv, mimotopes which bind CD antigens, cytokine receptors, interleukin receptors, hormone receptors, growth factor receptors, more particularly tyrosine kinase growth factor receptor of the ErbB family, wherein the photosensitizer is coupled to the binding protein via O6-alkylguanine-DNA alkyltransferase (hAGTm), a modified human DNA repair protein.

Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.

Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.

Abstract: Subject of the invention is a compound, consisting of a targeting moiety which specifically binds to a disease related cell surface marker, a nucleic acid which specifically induces cell death and a linker, wherein the linker covalently links the targeting moiety to the nucleic acid. Subject of the invention are also medicaments comprising the compound and their use as a medicament for the treatment of diseases, including proliferative diseases.